Mahamaya Lifesciences Ltd - 544611 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Mahamaya Lifesciences announced its audited financial results for FY26. The company reported a significant year-on-year growth with revenue up 24.50% to Rs.328.87 crore and net profit rising 28.97% to Rs.16.52 crore.
May 26 2026 13:13:48
Mahamaya Lifesciences Ltd - 544611 - Board Meeting Outcome for Audited Financial Results (Standalone & Consolidated) For The Half Year And Year Ended On 31.03.2026
Mahamaya Lifesciences reported FY26 cons. revenue of ₹328.87 crore, a 24.5% YoY increase, and net profit of ₹16.52 crore, up 28.9% YoY. Statutory auditors issued an unmodified opinion on both standalone and consolidated financial results for the period ended March 31, 2026.
May 25 2026 13:38:52
Mahamaya Lifesciences Ltd - 544611 - Board Meeting Intimation for Prior Intimation Of The Board Meeting Pursuant To Regulation 29(1) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
Mahamaya Lifesciences board will hold a meeting on May 25, 2026, to consider and approve its audited standalone and consolidated financial results for the half year and full financial year ended March 31, 2026.
May 20 2026 18:00:47
Mahamaya Lifesciences Ltd - 544611 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Mahamaya Lifesciences has rescheduled the utilization of its unutilized IPO proceeds of Rs. 32.79 crore, extending the timeline to March 31, 2028. This delay, representing 53% of the IPO funds, is attributed to project execution timelines for the Technical Manufacturing Plant.
May 15 2026 13:32:13
Read More